Patients
PD
ONCOLOGY, ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME, AML
Patient demographics and clinical characteristics are summarized in Patient demographics and baseline characteristicsECOG, Eastern Cooperative Oncology Group; PS, performance status; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; AZA, azacitidine; RBC, red blood cell.
The median treatment period was 2.0 months (range = 0.7–5.1). All patients discontinued the study treatment. Seven patients (50.0%) continued to receive the same combination treatment using commercially available venetoclax instead of the study drug after its approval. In the other seven patients, the primary reasons for discontinuation included the physician’s decision in three cases (21.4%), PD in two cases (14.2%) and AEs related to and not related to aggravation of AML in one case each (7.1%).